cancer biology

Cancer translated’s top blog posts of 2017

From basic science to survivorship and patient advocacy, the OHSU Knight Cancer Institute’s ‘Cancer translated’ blog explores new ideas and debates in cancer medicine. We sorted a year’s worth of posts to find the most heavily trafficked reports. Here are the top 10 in order of popularity:

Solving the problem of drug-resistant cancer

To discover ways to prevent or delay resistance to cancer therapies, a new NCI-funded center at OHSU is exploring how acute myeloid leukemia cells evolve and adapt.  

Check out the Knight Cancer pilot project award winners

Preventing skin cancer with a DNA-repair enzyme. Using zebrafish embryos to rapidly assess toxicity of anticancer drug combinations. Understanding how microRNAs modify cancer immunity. These are some of the ideas researchers are pursuing with the latest round of Knight Cancer Institute pilot project grants.

Outsmarting treatment-resistant prostate cancers

Aggressive prostate tumors can rapidly evolve to resist PARP inhibitors, but it may be possible to detect resistance early enough to counteract.   Two views of the structure of the DNA-repair protein PARP1 It was a surprising discovery that opened up a new avenue for treating prostate cancer. In recent years, studies have revealed that gene mutations long associated with breast and ovarian cancers – BRCA1 and BRCA2 – also play a significant role in driving … Read More

Oregon’s precision medicine pioneer targets earlier cancer detection

OHSU Knight Cancer Institute Director Brian Druker talks with Medscape about breaking out of one-size-fits-all thinking in cancer screening and prevention ____________________ “We are now in the process of building an entire program on what I call precision early detection of cancer,” said Brian Druker, M.D., “We are trying to be more accurate in taking the same precepts of precision medicine for advanced cancer and using them earlier.” If it works, Druker told Medscape’s editor-in-chief, … Read More

A new way to guide cancer immune therapy

Scrutinizing the immune cells infiltrating a tumor may reveal the cancer’s vulnerability or resistance to immune-based therapies.  

The cancer drug that “changed everything”

Understanding the earliest drivers of cancer formation can lead to less toxic and more effective treatments.   It transformed the outlook for people diagnosed with chronic myeloid leukemia. A disease with a three- to five-year life expectancy became, for most patients, a chronic, long-term condition managed with a daily pill. And this week, researchers published the outcomes of people treated for more than 10 years with the drug imatinib (Gleevec), ushered from lab to clinical … Read More

Why breast cancer is more dangerous for new moms

Breast cancers that emerge after a woman gives birth are significantly more deadly. Those diagnosed within five years of childbirth are about three times more likely to spread and give rise to life-threatening metastatic tumors. Researchers now are closing in on the reasons why.   Scientists at OHSU have discovered how the liver – one of the most common sites of breast cancer metastasis – becomes vulnerable to tumor invasion after childbirth. Using rodent models, … Read More

Knight Cancer signal achievements of 2016

The staff and faculty of the OHSU Knight Cancer Institute accomplished much together during the past year. Here’s a sampling of achievements that reflect the mission of delivering compassionate care and scientific discoveries that will end cancer as we know it:

The ‘Cancer translated’ blog top ten posts of 2016

The OHSU Knight Cancer Institute’s “Cancer translated” blog explores new findings, ideas and debates in cancer medicine, from basic biology, to clinical trials, to prevention, survivorship and patient advocacy. We sorted a year’s worth of posts to find the most heavily trafficked reports. Here’s the top 10 in order of popularity:

Solving the problem of drug-resistant cancer

Solving the problem of drug-resistant cancer

To discover ways to prevent or delay drug resistance in cancer, a new NCI-funded center at OHSU is exploring how acute myeloid leukemia cells evolve and adapt.